Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333031, India.
Department of Biological Sciences, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333031, India.
Life Sci. 2024 Apr 1;342:122509. doi: 10.1016/j.lfs.2024.122509. Epub 2024 Feb 22.
Acute kidney injury to chronic kidney disease (AKI-to-CKD) transition is a complex intermingling of characteristics of both AKI and CKD. Pathophysiologically, the transition lasts seven days after the AKI episode and thereafter silently progresses towards CKD. Growing reports confirm that the AKI-to-CKD transition is heavily regulated by epigenetic modifiers. Long non-coding RNAs (lncRNAs) share a diverse role in gene regulation at transcriptional and translational levels and have been reported to be involved in the regulation and progression of AKI-to-CKD transition. Several lncRNAs have been considered potential biomarkers for diagnosing kidney disease, including AKI and CKD. Targeting lncRNAs gives a promising therapeutic strategy against kidney diseases. The primitive role of lncRNA in the progression of the AKI-to-CKD transition is yet to be fully understood. As known, the lncRNAs could be used as a biomarker and a therapeutic target to halt the CKD development and progression after AKI. This review aims to deepen our understanding of the current knowledge regarding the involvement of lncRNAs in the AKI-to-CKD transition. This review primarily discusses the role of lncRNAs and the change in their mechanisms during different stages of kidney disease, such as in AKI, AKI-to-CKD transition, and CKD. Further, we have discussed the potential diagnostic and pharmacological outcomes of targeting lncRNAs to prevent or slow the progression of AKI-to-CKD transition.
急性肾损伤向慢性肾脏病（AKI-to-CKD）的转变是 AKI 和 CKD 两者特征的复杂交织。从病理生理学上讲，AKI 发作后持续 7 天，然后向 CKD 悄然进展。越来越多的报道证实，AKI-to-CKD 的转变受到表观遗传修饰物的严格调控。长链非编码 RNA（lncRNAs）在转录和翻译水平上具有多样化的基因调控作用，并且已被报道参与 AKI-to-CKD 转变的调控和进展。几种 lncRNAs 被认为是诊断肾脏疾病（包括 AKI 和 CKD）的潜在生物标志物。靶向 lncRNAs 为治疗肾脏疾病提供了有希望的策略。lncRNA 在 AKI-to-CKD 转变中的原始作用尚未得到充分理解。众所周知，lncRNA 可作为生物标志物和治疗靶点，在 AKI 后阻止 CKD 的发生和进展。本综述旨在深入了解目前关于 lncRNA 参与 AKI-to-CKD 转变的知识。本综述主要讨论了 lncRNA 在不同肾脏疾病阶段（如 AKI、AKI-to-CKD 转变和 CKD）中的作用及其机制的变化。此外，我们还讨论了靶向 lncRNA 以预防或减缓 AKI-to-CKD 转变进展的潜在诊断和药理学结果。
